264 related articles for article (PubMed ID: 11142756)
1. Tay-Sachs disease carrier screening: a 21-year experience.
D'Souza G; McCann CL; Hedrick J; Fairley C; Nagel HL; Kushner JD; Kessel R
Genet Test; 2000; 4(3):257-63. PubMed ID: 11142756
[TBL] [Abstract][Full Text] [Related]
2. Screening for genetic disorders among Jews: how should the Tay-Sachs screening program be continued?
Zlotogora J; Leventhal A
Isr Med Assoc J; 2000 Sep; 2(9):665-7. PubMed ID: 11062764
[TBL] [Abstract][Full Text] [Related]
3. Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews.
Lew RM; Proos AL; Burnett L; Delatycki M; Bankier A; Fietz MJ
Med J Aust; 2012 Dec; 197(11):652-4. PubMed ID: 23230938
[TBL] [Abstract][Full Text] [Related]
4. Tay-Sachs disease--carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network.
Kaback M; Lim-Steele J; Dabholkar D; Brown D; Levy N; Zeiger K
JAMA; 1993 Nov; 270(19):2307-15. PubMed ID: 8230592
[TBL] [Abstract][Full Text] [Related]
5. The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program.
Rozenberg R; Pereira Lda V
Sao Paulo Med J; 2001 Jul; 119(4):146-9. PubMed ID: 11500789
[TBL] [Abstract][Full Text] [Related]
6. Screening for carriers of Tay-Sachs disease in the ultraorthodox Ashkenazi Jewish community in Israel.
Broide E; Zeigler M; Eckstein J; Bach G
Am J Med Genet; 1993 Aug; 47(2):213-5. PubMed ID: 8213907
[TBL] [Abstract][Full Text] [Related]
7. Comparison of enzyme and DNA analysis in a Tay-Sachs disease carrier screening program.
Yoo HW; Astrin KH; Desnick RJ
J Korean Med Sci; 1993 Feb; 8(1):84-91. PubMed ID: 8343225
[TBL] [Abstract][Full Text] [Related]
8. Tay-Sachs disease carrier screening: a model for prevention of genetic disease.
Kaplan F
Genet Test; 1998; 2(4):271-92. PubMed ID: 10464605
[TBL] [Abstract][Full Text] [Related]
9. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.
Kronn D; Jansen V; Ostrer H
Arch Intern Med; 1998 Apr; 158(7):777-81. PubMed ID: 9554684
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Tay-Sachs disease screening program.
Gason AA; Sheffield E; Bankier A; Aitken MA; Metcalfe S; Barlow Stewart K; Delatycki MB
Clin Genet; 2003 May; 63(5):386-92. PubMed ID: 12752571
[TBL] [Abstract][Full Text] [Related]
11. The Tay-Sachs disease gene in North American Jewish populations: geographic variations and origin.
Petersen GM; Rotter JI; Cantor RM; Field LL; Greenwald S; Lim JS; Roy C; Schoenfeld V; Lowden JA; Kaback MM
Am J Hum Genet; 1983 Nov; 35(6):1258-69. PubMed ID: 6650504
[TBL] [Abstract][Full Text] [Related]
12. Knowledge and attitudes toward Tay-Sachs disease among a college student population.
Austein CF; Seashore MR; Mick SS
Yale J Biol Med; 1981; 54(5):345-54. PubMed ID: 7336765
[TBL] [Abstract][Full Text] [Related]
13. Heterozygote screening for Tay-Sachs disease: past successes and future challenges.
Natowicz MR; Prence EM
Curr Opin Pediatr; 1996 Dec; 8(6):625-9. PubMed ID: 9018448
[TBL] [Abstract][Full Text] [Related]
14. Ethical Issues with Genetic Testing for Tay-Sachs.
Clayton T
J Christ Nurs; 2017; 34(4):246-249. PubMed ID: 28902054
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a multi-disease carrier screening programme in Ashkenazi Jewish high schools.
Ioannou L; Massie J; Lewis S; Petrou V; Gason A; Metcalfe S; Aitken MA; Bankier A; Delatycki MB
Clin Genet; 2010 Jul; 78(1):21-31. PubMed ID: 20597919
[TBL] [Abstract][Full Text] [Related]
16. Population-based Tay-Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing.
Schneider A; Nakagawa S; Keep R; Dorsainville D; Charrow J; Aleck K; Hoffman J; Minkoff S; Finegold D; Sun W; Spencer A; Lebow J; Zhan J; Apfelroth S; Schreiber-Agus N; Gross S
Am J Med Genet A; 2009 Nov; 149A(11):2444-7. PubMed ID: 19876898
[TBL] [Abstract][Full Text] [Related]
17. Assessing the potential success of cystic fibrosis carrier screening: lessons learned from Tay-Sachs disease and beta-thalassemia.
Laberge AM; Watts C; Porter K; Burke W
Public Health Genomics; 2010; 13(5):310-9. PubMed ID: 19864874
[TBL] [Abstract][Full Text] [Related]
18. Improving accuracy of Tay Sachs carrier screening of the non-Jewish population: analysis of 34 carriers and six late-onset patients with HEXA enzyme and DNA sequence analysis.
Park NJ; Morgan C; Sharma R; Li Y; Lobo RM; Redman JB; Salazar D; Sun W; Neidich JA; Strom CM
Pediatr Res; 2010 Feb; 67(2):217-20. PubMed ID: 19858779
[TBL] [Abstract][Full Text] [Related]
19. ACOG committee opinion. Number 318, October 2005. Screening for Tay-Sachs disease.
ACOG Committee on Genetics
Obstet Gynecol; 2005 Oct; 106(4):893-4. PubMed ID: 16199656
[TBL] [Abstract][Full Text] [Related]
20. Prenatal genetic carrier testing using triple disease screening.
Eng CM; Schechter C; Robinowitz J; Fulop G; Burgert T; Levy B; Zinberg R; Desnick RJ
JAMA; 1997 Oct; 278(15):1268-72. PubMed ID: 9333269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
